Drawing for OPEONGO

USPTO serial 50083285

OPEONGO

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
—
Law office
—

What this means

Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.

Status 630: Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies.

Need help with OPEONGO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roy D. Gross

Roy D. Gross The Roy Gross Law Firm, LLC19 Old Kings Hwy SSuite 200Darien, CT 06820

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the treatment of: extracellular matrix diseases, fibrotic diseases, inflammatory diseases, age-related diseases, degenerative diseases, regeneration disorders and cancer; Antibodies for medical purposes; Therapeutic antibodies for the treatment of: extracellular matrix diseases, fibrotic diseases, inflammatory diseases, age-related diseases, degenerative diseases, regeneration disorders and cancerACTIVE—
042Drug discovery services; Biochemical analysis services in the field of drug discovery; Biochemical analysis services in the field of medical diagnosis of disease; Biochemical analysis services in the field of drug target discovery; Pharmaceutical drug development services; Drug discovery services for: modulation of the extracellular matrix, prevention and treatment of fibrotic diseases, treating inflammatory diseases, treating age-related diseases, treating degenerative diseases, treating tissue repair, treating regeneration disorders, and chemotherapy; Scientific research for medical purposes in the area of fibrosis, cancerous diseases, modulation of the extracellular matrix, fibrotic diseases, inflammatory diseases, age-related diseases, degenerative diseases, tissue repair, regeneration disorders; Biomedical research in the field of the extra cellular matrix and fibrosis; providing online non-downloadable software for modeling the extracellular matrix for use in drug and target discovery; providing online non-downloadable software for drug discovery in the field of: fibrosis, cancerous diseases, modulation of the extracellular matrix, fibrotic diseases, inflammatory diseases, age-related diseases, degenerative diseases, tissue repair, and regeneration disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 28, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 1, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 1, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance